Gérardin-Marais Marie, Victorri-Vigneau Caroline, Allain-Veyrac Gwenaëlle, Chaslerie Anicet, Nicolas Maryse, Sarraf Nathalie, Pivette Jacques, Jolliet Pascale
Service de Pharmacologie Clinique, CHU de Nantes, France.
Eur J Clin Pharmacol. 2008 Apr;64(4):433-7. doi: 10.1007/s00228-007-0431-0. Epub 2008 Jan 5.
Because the elderly are often treated by multiple-drug regimens, their iatrogenic risks are considerably raised. However, despite the serious side-effects that diuretic agents may have in this population, SPCs (summary of product characteristics) do not specify how often serum chemistry should be monitored. This study of long-term diuretic therapy prescription and monitoring in elderly patients was conducted by the Department of Clinical Pharmacology of the Nantes teaching hospital in collaboration with the medical department of the French national health insurance scheme.
Data were extracted from the French national health insurance database. Patients were 75 years old or more and had been receiving a diuretic agent for 1 year or longer. The patients were classified into two groups: one group included those patients whose serum chemistry had been monitored at least once (electrolyte levels and/or urea and creatinine blood levels); the other group included the non-monitored patients.
Mean patient age was 80+/-4.6 (SD) years. The non-monitored patients represented 22.8% of the cohort. The at-risk patients were mainly women suffering from no severe disease, treated by a single practitioner (often a general practitioner) and/or always receiving the same type of diuretic agent.
Many elderly patients receiving diuretic agents do not benefit from regular serum chemistry monitoring. The prescription of serum chemistry assays is correlated to the presence of various patient-related risk factors. Recommendations should be made to help practitioners to ensure a minimal serum chemistry monitoring in all elderly patients receiving diuretics.
由于老年人常采用多种药物联合治疗方案,其医源性风险显著增加。然而,尽管利尿剂在该人群中可能产生严重副作用,但药品说明书并未明确规定血清生化指标的监测频率。这项针对老年患者长期利尿剂治疗处方及监测的研究由南特教学医院临床药理学科与法国国家医疗保险计划医疗部门合作开展。
数据取自法国国家医疗保险数据库。患者年龄在75岁及以上,且接受利尿剂治疗达1年或更长时间。患者被分为两组:一组包括血清生化指标至少监测过一次的患者(电解质水平和/或尿素及肌酐血水平);另一组为未监测的患者。
患者平均年龄为80±4.6(标准差)岁。未监测的患者占队列的22.8%。高危患者主要是无严重疾病的女性,由单一医生(通常是全科医生)治疗和/或始终接受同类型利尿剂治疗。
许多接受利尿剂治疗的老年患者未受益于定期血清生化监测。血清生化检测的处方与多种患者相关风险因素有关。应提出建议,以帮助医生确保对所有接受利尿剂治疗的老年患者进行最低限度的血清生化监测。